肿瘤的可塑性与免疫治疗抵抗性
Tumor Plasticity and Resistance to Immunotherapy.
机构信息
Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
出版信息
Trends Cancer. 2020 May;6(5):432-441. doi: 10.1016/j.trecan.2020.02.001. Epub 2020 Mar 4.
Abstract
Tumor cell plasticity exhibited as an epithelial-mesenchymal transition (EMT) has been identified as a major obstacle for the effective treatment of many cancers. This process, which involves the dedifferentiation of epithelial tumor cells towards a motile, metastatic, and mesenchymal tumor phenotype, mediates resistance to conventional therapies and small-molecule targeted therapies. In this review, we highlight current research correlating the role of tumor plasticity with resistance to current immunotherapy approaches and discuss future and ongoing combination immunotherapy strategies to reduce tumor cell plasticity-driven resistance in cancer.
摘要
肿瘤细胞的可塑性表现为上皮-间充质转化（EMT），已被确定为许多癌症有效治疗的主要障碍。这个过程涉及上皮肿瘤细胞向运动性、转移性和间充质肿瘤表型的去分化，介导了对传统治疗和小分子靶向治疗的耐药性。在这篇综述中，我们强调了当前研究将肿瘤可塑性的作用与对当前免疫治疗方法的耐药性相关联，并讨论了未来和正在进行的联合免疫治疗策略，以减少癌症中肿瘤细胞可塑性驱动的耐药性。
相似文献
1
Tumor Plasticity and Resistance to Immunotherapy.肿瘤的可塑性与免疫治疗抵抗性
Trends Cancer. 2020 May;6(5):432-441. doi: 10.1016/j.trecan.2020.02.001. Epub 2020 Mar 4.
2
Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.EMT 与 PD-L1 信号转导之间的通讯：肿瘤免疫逃逸的新见解。
Cancer Lett. 2020 Jan 1;468:72-81. doi: 10.1016/j.canlet.2019.10.013. Epub 2019 Oct 9.
3
Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.纳米胶束保护紫杉醇的免疫激活作用，并使肿瘤对抗 PD-1 免疫治疗敏感。
Theranostics. 2020 Jul 9;10(18):8382-8399. doi: 10.7150/thno.45391. eCollection 2020.
4
Epithelial-mesenchymal transition: When tumor cells meet myeloid-derived suppressor cells.上皮-间充质转化：当肿瘤细胞遇到髓源抑制细胞时。
Biochim Biophys Acta Rev Cancer. 2021 Aug;1876(1):188564. doi: 10.1016/j.bbcan.2021.188564. Epub 2021 May 8.
5
Clinical Evolution of Epithelial-Mesenchymal Transition in Human Carcinomas.人类癌中上皮-间充质转化的临床演变。
Cancer Res. 2020 Jan 15;80(2):304-318. doi: 10.1158/0008-5472.CAN-18-3539. Epub 2019 Nov 15.
6
Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance.肿瘤微环境和上皮间质转化作为克服肿瘤多药耐药的靶点。
Drug Resist Updat. 2020 Dec;53:100715. doi: 10.1016/j.drup.2020.100715. Epub 2020 Jun 20.
7
PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.PI3Kγδ 抑制剂联合放疗增强 PD-1 阻断在同种小鼠乳腺癌和人源化患者来源异种移植模型中的抗肿瘤免疫效应。
Eur J Cancer. 2021 Nov;157:450-463. doi: 10.1016/j.ejca.2021.08.029. Epub 2021 Oct 1.
8
Advances in the Study of Antitumour Immunotherapy for Newcastle Disease Virus.新城疫病毒抗肿瘤免疫治疗的研究进展。
Int J Med Sci. 2021 Mar 30;18(11):2294-2302. doi: 10.7150/ijms.59185. eCollection 2021.
9
Gastrointestinal cancer stem cells as targets for innovative immunotherapy.胃肠道癌症干细胞作为创新免疫疗法的靶点。
World J Gastroenterol. 2020 Apr 14;26(14):1580-1593. doi: 10.3748/wjg.v26.i14.1580.
10
Tackling Resistance to Cancer Immunotherapy: What Do We Know?攻克癌症免疫疗法耐药性：我们了解多少？
Molecules. 2020 Sep 8;25(18):4096. doi: 10.3390/molecules25184096.
引用本文的文献
1
Phenotypic Plasticity, Non-genetic Mechanisms, and Immune Drug Resistance in Cancer.癌症中的表型可塑性、非遗传机制与免疫耐药性
Cancer Treat Res. 2025;129:309-324. doi: 10.1007/978-3-031-97242-3_14.
2
Treatment of NSCLC after chemoimmunotherapy - are we making headway?化疗免疫治疗后非小细胞肺癌的治疗——我们有进展吗？
Nat Rev Clin Oncol. 2025 Aug 14. doi: 10.1038/s41571-025-01061-7.
3
Immunotherapy in GI Cancers: Lessons from Key Trials and Future Clinical Applications.胃肠道癌症的免疫疗法：关键试验的经验教训及未来临床应用
Antibodies (Basel). 2025 Jul 11;14(3):58. doi: 10.3390/antib14030058.
4
CXCL8 is essential for cervical cancer cell acquired radioresistance and acts as a promising therapeutic target in cervical cancer.CXCL8对于宫颈癌细胞获得性放射抗性至关重要，并且作为宫颈癌中一个有前景的治疗靶点。
Sci Rep. 2025 Jul 1;15(1):20467. doi: 10.1038/s41598-025-05435-w.
5
Evolutionary and immune microenvironment dynamics during neoadjuvant treatment of esophageal adenocarcinoma.食管腺癌新辅助治疗期间的进化与免疫微环境动态变化
Nat Cancer. 2025 May 14. doi: 10.1038/s43018-025-00955-w.
6
Assessing the impact of CD73 inhibition on overcoming anti-EGFR resistance in glioma cells.评估CD73抑制对克服胶质瘤细胞中抗表皮生长因子受体（EGFR）耐药性的影响。
Oncol Res. 2025 Mar 19;33(4):951-964. doi: 10.32604/or.2024.055508. eCollection 2025.
7
Accumulation of CD38 in Hybrid Epithelial/Mesenchymal Cells Promotes Immune Remodeling and Metastasis in Breast Cancer.CD38在杂交上皮/间充质细胞中的积累促进乳腺癌的免疫重塑和转移。
Cancer Res. 2025 Mar 3;85(5):894-911. doi: 10.1158/0008-5472.CAN-24-0400.
8
Resistance mechanisms to immune checkpoint inhibitors: updated insights.免疫检查点抑制剂的耐药机制：最新见解
Mol Cancer. 2025 Jan 15;24(1):20. doi: 10.1186/s12943-024-02212-7.
9
Inhibition of the chemokine receptors CXCR1 and CXCR2 synergizes with docetaxel for effective tumor control and remodeling of the immune microenvironment of HPV-negative head and neck cancer models.趋化因子受体CXCR1和CXCR2的抑制与多西他赛协同作用，可有效控制HPV阴性头颈癌模型的肿瘤并重塑其免疫微环境。
J Exp Clin Cancer Res. 2024 Dec 5;43(1):318. doi: 10.1186/s13046-024-03240-3.
10
STAMBPL1/TRIM21 Balances AXL Stability Impacting Mesenchymal Phenotype and Immune Response in KIRC.STAMBPL1/TRIM21平衡AXL稳定性，影响肾透明细胞癌的间充质表型和免疫反应。
Adv Sci (Weinh). 2025 Jan;12(1):e2405083. doi: 10.1002/advs.202405083. Epub 2024 Nov 11.
本文引用的文献
1
Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models.抑制 MDSC 迁移：一种 CXCR1/2 抑制剂，增强头颈部癌症模型中的 NK 细胞免疫治疗。
Clin Cancer Res. 2020 Mar 15;26(6):1420-1431. doi: 10.1158/1078-0432.CCR-19-2625. Epub 2019 Dec 17.
2
Higher matrix stiffness as an independent initiator triggers epithelial-mesenchymal transition and facilitates HCC metastasis.较高的基质硬度作为一个独立的启动子触发上皮-间充质转化，并促进 HCC 转移。
J Hematol Oncol. 2019 Nov 8;12(1):112. doi: 10.1186/s13045-019-0795-5.
3
Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma.转移性黑色素瘤中 β-连环蛋白通路激活或 PTEN 缺失与免疫治疗继发性耐药相关。
J Immunother Cancer. 2019 Nov 8;7(1):295. doi: 10.1186/s40425-019-0780-0.
4
A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer.一项在晚期癌症患者中使用多靶向重组腺病毒 5（CEA/MUC1/Brachyury）免疫治疗疫苗方案的 I 期临床试验。
Oncologist. 2020 Jun;25(6):479-e899. doi: 10.1634/theoncologist.2019-0608. Epub 2019 Oct 8.
5
c-Met activation leads to the establishment of a TGFβ-receptor regulatory network in bladder cancer progression.c-Met 激活导致 TGFβ 受体调节网络在膀胱癌进展中的建立。
Nat Commun. 2019 Sep 25;10(1):4349. doi: 10.1038/s41467-019-12241-2.
6
AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity.AXL 靶向治疗克服了人肺癌细胞对 NK 和 CTL 介导的细胞毒性的抗性。
Cancer Immunol Res. 2019 Nov;7(11):1789-1802. doi: 10.1158/2326-6066.CIR-18-0903. Epub 2019 Sep 5.
7
Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors.HuMax-IL8（BMS-986253）治疗转移性或不可切除实体瘤患者的 I 期临床试验。HuMax-IL8 是一种抗 IL-8 单克隆抗体。
J Immunother Cancer. 2019 Sep 5;7(1):240. doi: 10.1186/s40425-019-0706-x.
8
β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma.β-连环蛋白激活促进肝癌的免疫逃逸和抗 PD-1 治疗耐药性。
Cancer Discov. 2019 Aug;9(8):1124-1141. doi: 10.1158/2159-8290.CD-19-0074. Epub 2019 Jun 11.
9
Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?免疫检查点阻断的耐药机制：为何检查点抑制剂免疫疗法并非对所有患者都有效？
Am Soc Clin Oncol Educ Book. 2019 Jan;39:147-164. doi: 10.1200/EDBK_240837. Epub 2019 May 17.
10
EMT and Cancer: More Than Meets the Eye.急诊医疗技术员和癌症：比表面所见更多。
Dev Cell. 2019 May 6;49(3):313-316. doi: 10.1016/j.devcel.2019.04.026.
Zotero 插件